المؤلفون: Lee, Ay, Kamphuisen, Pw, Meyer, G, Bauersachs, R, Janas, Ms, Jarner, Mf, Khorana, Aa, Bella, Sr, Cerana, S, Zarbá, Jj, Johannes, A, Barrios, Ch, Borba, Ra, Cesario, F, de Azevedo, S, Ferreira Filho, Af, Franke, Fa, Padilha, S, Paiva, Qr, Pimenta, A, Rerin, J, Rigo, R, Rocha Van Eyll, Sb, Santos, Bg, Vacaro, G, Anastasov, V, Dragneva, T, Georgiev, G, Champion, P, Kuruvilla, P, Gonzalez, C, Ditl, P, Förster, J, Lubomir, B, Vydra, J, Abo El Hassan, R, Sabri, S, Allahloubi, N, Elzawawy, A, Ezzat, Ss, Sabry el, Km, Bacchus, L, Beyer Westendorf, J, Kamphausen, U, Niederwieser, D, Ostermann, H, Sosada, M, Anagnostopoulos, N, Fountzilas, G, Ioannou, C, Liapis, C, Barrios, Sf, Atilli, S, Balsubramanian, S, Bondarde, S, Desai, Sc, Deshmukh, C, Singh, Dp, Gharami, F, Goyal, L, Gupta, S, Gupte, S, Mukherjee, Kk, Krishnan, S, Kumar, K, Mehta, A, Mishra, K, Naik, R, Pawar, S, Rajnish, Vn, Warrier, N, Brenner, B, Gavish, I, Lugassy, G, Kolin, M, Enrico, B, Mazzucconi, Maria Gabriella, Visani, G, Awidi, A, Novikovs, N, Miscuks, J, Abigerges, D, Farhat, F, Khoueiry, P, Makarem, J, Alvarez Ordorica, O, Anaya Santacruz, E, Calderillo Ruiz, G, De la Concha Ureta, Hj, Pantigoso Wuilbert, Sr, Philco, M, Romero Pineda, A, Vargas Queszada, Ea, Gawrychowski, K, Witkiewicz, W, Macias, E, Teixeira, E, Ciuleanu, Te, Ligia, Cc, Lungulescu, D, Manolescu, Ig, Rodica, A, Volovat, C, Burov, Y, Katelnitsky, I, Svistov, D, Ahmad, K, Algahtani, F, Al Zahrani, H, Qari, M, Jovanovic, D, Milanovic, N, Perin, B, Stojanovic, V, Tomasic, L, Chovanec, J, Herman, O, Kissova, V, Sasvary, F, Špánik, S, Szentivanyi, M, Barón, F, Gallardo, E, Jiménez, D, Remedios, O, Sanchez, A, Engelbrecht, J, Jonas, N, Mcadam, G, Patel, M, Rapoport, B, Robertson, B, Oh, D, Kim, H, Kim, Hk, Kim, Hj, Kim, Hs, Ahn, Js, Chung, J, Jang, J, Park, Ku, Shin, Sw, Kim, Sh, Yoon, Ss, Kim, Yk, Chiu, Cf, Chang, Cs, Liu, Jh, Rau, Km, Chen, Sw, Chittima, S, Ekkapong, T, Nonglak, K, Pantep, A, Pramook, M, Thanakrit, S, Patrapim, S, Sumitra, T, Udomluck, C, Kobza, I, Nykonenko, O, Prasol, V, Vladychuk, I.

المساهمون: Cardiovascular Centre (CVC), Vascular Ageing Programme (VAP)

المصدر: JAMA-Journal of the American Medical Association, 314(7), 677-686. AMER MEDICAL ASSOC

مصطلحات موضوعية: Male, medicine.medical_specialty, Hemorrhage, DISEASE, law.invention, Tinzaparin, Randomized controlled trial, law, Recurrence, Internal medicine, Neoplasms, medicine, Humans, Cumulative incidence, International Normalized Ratio, cardiovascular diseases, Aged, Venous Thrombosis, MALIGNANCY, RISK, Heparin, business.industry, Medicine (all), Hazard ratio, Low-Molecular-Weight, Warfarin, Anticoagulants, General Medicine, Venous Thromboembolism, MOLECULAR-WEIGHT HEPARIN, Heparin, Low-Molecular-Weight, Middle Aged, medicine.disease, Thrombosis, Survival Analysis, PREVENTION, Surgery, Pulmonary embolism, Venous thrombosis, Female, business, Pulmonary Embolism, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e10bee9f3335a8c83887b7dcd67aaebd
https://research.rug.nl/en/publications/10156842-f748-4723-9092-5917677ba555

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

المؤلفون: Sternberg CN; From the Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy; Ludwig Oncology Unit, Austin Hospital, Melbourne, Australia; National Oncological Institute, Klenová, Bratislava, Slovakia; Department of Oncology, Military Institute of Medicine, Warsaw, Poland; Department of Urology, Seoul National University College of Medicine, Seoul, Korea; The South West Wales Cancer Institute, Singleton Hospital, Swansea; Cancer Research UK, Department of Medical Oncology, University of Manchester; Christie Hospital National Health Services Foundation Trust, Manchester, United Kingdom; Oncology Research Unit, Oncology Service, Hospital Sao Lucas, Pontifícia Universidade Católica do Rio Grande do Sol, Porto Alegre, Brazil; Division of Medical Oncology and Hematology, Fundación Arturo López Pérez, Santiago, Chile; Chelyabinsk Regional Oncology Center, Chelyabinsk, Russian Federation; Krankenhaus Heitzing, mit Neurologischem Zentrum Rosenhugel, Vienna, Austria; Centro Médico San Roque, Tucumán, Argentina; GlaxoSmithKline, Collegeville, PA; and GlaxoSmithKline, Research Triangle Park, NC., Davis ID; From the Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy; Ludwig Oncology Unit, Austin Hospital, Melbourne, Australia; National Oncological Institute, Klenová, Bratislava, Slovakia; Department of Oncology, Military Institute of Medicine, Warsaw, Poland; Department of Urology, Seoul National University College of Medicine, Seoul, Korea; The South West Wales Cancer Institute, Singleton Hospital, Swansea; Cancer Research UK, Department of Medical Oncology, University of Manchester; Christie Hospital National Health Services Foundation Trust, Manchester, United Kingdom; Oncology Research Unit, Oncology Service, Hospital Sao Lucas, Pontifícia Universidade Católica do Rio Grande do Sol, Porto Alegre, Brazil; Division of Medical Oncology and Hematology, Fundación Arturo López Pérez, Santiago, Chile; Chelyabinsk Regional Oncology Center, Chelyabinsk, Russian Federation; Krankenhaus Heitzing, mit Neurologischem Zentrum Rosenhugel, Vienna, Austria; Centro Médico San Roque, Tucumán, Argentina; GlaxoSmithKline, Collegeville, PA; and GlaxoSmithKline, Research Triangle Park, NC., Mardiak J; From the Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy; Ludwig Oncology Unit, Austin Hospital, Melbourne, Australia; National Oncological Institute, Klenová, Bratislava, Slovakia; Department of Oncology, Military Institute of Medicine, Warsaw, Poland; Department of Urology, Seoul National University College of Medicine, Seoul, Korea; The South West Wales Cancer Institute, Singleton Hospital, Swansea; Cancer Research UK, Department of Medical Oncology, University of Manchester; Christie Hospital National Health Services Foundation Trust, Manchester, United Kingdom; Oncology Research Unit, Oncology Service, Hospital Sao Lucas, Pontifícia Universidade Católica do Rio Grande do Sol, Porto Alegre, Brazil; Division of Medical Oncology and Hematology, Fundación Arturo López Pérez, Santiago, Chile; Chelyabinsk Regional Oncology Center, Chelyabinsk, Russian Federation; Krankenhaus Heitzing, mit Neurologischem Zentrum Rosenhugel, Vienna, Austria; Centro Médico San Roque, Tucumán, Argentina; GlaxoSmithKline, Collegeville, PA; and GlaxoSmithKline, Research Triangle Park, NC., Szczylik C; From the Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy; Ludwig Oncology Unit, Austin Hospital, Melbourne, Australia; National Oncological Institute, Klenová, Bratislava, Slovakia; Department of Oncology, Military Institute of Medicine, Warsaw, Poland; Department of Urology, Seoul National University College of Medicine, Seoul, Korea; The South West Wales Cancer Institute, Singleton Hospital, Swansea; Cancer Research UK, Department of Medical Oncology, University of Manchester; Christie Hospital National Health Services Foundation Trust, Manchester, United Kingdom; Oncology Research Unit, Oncology Service, Hospital Sao Lucas, Pontifícia Universidade Católica do Rio Grande do Sol, Porto Alegre, Brazil; Division of Medical Oncology and Hematology, Fundación Arturo López Pérez, Santiago, Chile; Chelyabinsk Regional Oncology Center, Chelyabinsk, Russian Federation; Krankenhaus Heitzing, mit Neurologischem Zentrum Rosenhugel, Vienna, Austria; Centro Médico San Roque, Tucumán, Argentina; GlaxoSmithKline, Collegeville, PA; and GlaxoSmithKline, Research Triangle Park, NC., Lee E; From the Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy; Ludwig Oncology Unit, Austin Hospital, Melbourne, Australia; National Oncological Institute, Klenová, Bratislava, Slovakia; Department of Oncology, Military Institute of Medicine, Warsaw, Poland; Department of Urology, Seoul National University College of Medicine, Seoul, Korea; The South West Wales Cancer Institute, Singleton Hospital, Swansea; Cancer Research UK, Department of Medical Oncology, University of Manchester; Christie Hospital National Health Services Foundation Trust, Manchester, United Kingdom; Oncology Research Unit, Oncology Service, Hospital Sao Lucas, Pontifícia Universidade Católica do Rio Grande do Sol, Porto Alegre, Brazil; Division of Medical Oncology and Hematology, Fundación Arturo López Pérez, Santiago, Chile; Chelyabinsk Regional Oncology Center, Chelyabinsk, Russian Federation; Krankenhaus Heitzing, mit Neurologischem Zentrum Rosenhugel, Vienna, Austria; Centro Médico San Roque, Tucumán, Argentina; GlaxoSmithKline, Collegeville, PA; and GlaxoSmithKline, Research Triangle Park, NC., Wagstaff J; From the Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy; Ludwig Oncology Unit, Austin Hospital, Melbourne, Australia; National Oncological Institute, Klenová, Bratislava, Slovakia; Department of Oncology, Military Institute of Medicine, Warsaw, Poland; Department of Urology, Seoul National University College of Medicine, Seoul, Korea; The South West Wales Cancer Institute, Singleton Hospital, Swansea; Cancer Research UK, Department of Medical Oncology, University of Manchester; Christie Hospital National Health Services Foundation Trust, Manchester, United Kingdom; Oncology Research Unit, Oncology Service, Hospital Sao Lucas, Pontifícia Universidade Católica do Rio Grande do Sol, Porto Alegre, Brazil; Division of Medical Oncology and Hematology, Fundación Arturo López Pérez, Santiago, Chile; Chelyabinsk Regional Oncology Center, Chelyabinsk, Russian Federation; Krankenhaus Heitzing, mit Neurologischem Zentrum Rosenhugel, Vienna, Austria; Centro Médico San Roque, Tucumán, Argentina; GlaxoSmithKline, Collegeville, PA; and GlaxoSmithKline, Research Triangle Park, NC., Barrios CH; From the Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy; Ludwig Oncology Unit, Austin Hospital, Melbourne, Australia; National Oncological Institute, Klenová, Bratislava, Slovakia; Department of Oncology, Military Institute of Medicine, Warsaw, Poland; Department of Urology, Seoul National University College of Medicine, Seoul, Korea; The South West Wales Cancer Institute, Singleton Hospital, Swansea; Cancer Research UK, Department of Medical Oncology, University of Manchester; Christie Hospital National Health Services Foundation Trust, Manchester, United Kingdom; Oncology Research Unit, Oncology Service, Hospital Sao Lucas, Pontifícia Universidade Católica do Rio Grande do Sol, Porto Alegre, Brazil; Division of Medical Oncology and Hematology, Fundación Arturo López Pérez, Santiago, Chile; Chelyabinsk Regional Oncology Center, Chelyabinsk, Russian Federation; Krankenhaus Heitzing, mit Neurologischem Zentrum Rosenhugel, Vienna, Austria; Centro Médico San Roque, Tucumán, Argentina; GlaxoSmithKline, Collegeville, PA; and GlaxoSmithKline, Research Triangle Park, NC., Salman P; From the Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy; Ludwig Oncology Unit, Austin Hospital, Melbourne, Australia; National Oncological Institute, Klenová, Bratislava, Slovakia; Department of Oncology, Military Institute of Medicine, Warsaw, Poland; Department of Urology, Seoul National University College of Medicine, Seoul, Korea; The South West Wales Cancer Institute, Singleton Hospital, Swansea; Cancer Research UK, Department of Medical Oncology, University of Manchester; Christie Hospital National Health Services Foundation Trust, Manchester, United Kingdom; Oncology Research Unit, Oncology Service, Hospital Sao Lucas, Pontifícia Universidade Católica do Rio Grande do Sol, Porto Alegre, Brazil; Division of Medical Oncology and Hematology, Fundación Arturo López Pérez, Santiago, Chile; Chelyabinsk Regional Oncology Center, Chelyabinsk, Russian Federation; Krankenhaus Heitzing, mit Neurologischem Zentrum Rosenhugel, Vienna, Austria; Centro Médico San Roque, Tucumán, Argentina; GlaxoSmithKline, Collegeville, PA; and GlaxoSmithKline, Research Triangle Park, NC., Gladkov OA; From the Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy; Ludwig Oncology Unit, Austin Hospital, Melbourne, Australia; National Oncological Institute, Klenová, Bratislava, Slovakia; Department of Oncology, Military Institute of Medicine, Warsaw, Poland; Department of Urology, Seoul National University College of Medicine, Seoul, Korea; The South West Wales Cancer Institute, Singleton Hospital, Swansea; Cancer Research UK, Department of Medical Oncology, University of Manchester; Christie Hospital National Health Services Foundation Trust, Manchester, United Kingdom; Oncology Research Unit, Oncology Service, Hospital Sao Lucas, Pontifícia Universidade Católica do Rio Grande do Sol, Porto Alegre, Brazil; Division of Medical Oncology and Hematology, Fundación Arturo López Pérez, Santiago, Chile; Chelyabinsk Regional Oncology Center, Chelyabinsk, Russian Federation; Krankenhaus Heitzing, mit Neurologischem Zentrum Rosenhugel, Vienna, Austria; Centro Médico San Roque, Tucumán, Argentina; GlaxoSmithKline, Collegeville, PA; and GlaxoSmithKline, Research Triangle Park, NC., Kavina A; From the Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy; Ludwig Oncology Unit, Austin Hospital, Melbourne, Australia; National Oncological Institute, Klenová, Bratislava, Slovakia; Department of Oncology, Military Institute of Medicine, Warsaw, Poland; Department of Urology, Seoul National University College of Medicine, Seoul, Korea; The South West Wales Cancer Institute, Singleton Hospital, Swansea; Cancer Research UK, Department of Medical Oncology, University of Manchester; Christie Hospital National Health Services Foundation Trust, Manchester, United Kingdom; Oncology Research Unit, Oncology Service, Hospital Sao Lucas, Pontifícia Universidade Católica do Rio Grande do Sol, Porto Alegre, Brazil; Division of Medical Oncology and Hematology, Fundación Arturo López Pérez, Santiago, Chile; Chelyabinsk Regional Oncology Center, Chelyabinsk, Russian Federation; Krankenhaus Heitzing, mit Neurologischem Zentrum Rosenhugel, Vienna, Austria; Centro Médico San Roque, Tucumán, Argentina; GlaxoSmithKline, Collegeville, PA; and GlaxoSmithKline, Research Triangle Park, NC., Zarbá JJ; From the Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy; Ludwig Oncology Unit, Austin Hospital, Melbourne, Australia; National Oncological Institute, Klenová, Bratislava, Slovakia; Department of Oncology, Military Institute of Medicine, Warsaw, Poland; Department of Urology, Seoul National University College of Medicine, Seoul, Korea; The South West Wales Cancer Institute, Singleton Hospital, Swansea; Cancer Research UK, Department of Medical Oncology, University of Manchester; Christie Hospital National Health Services Foundation Trust, Manchester, United Kingdom; Oncology Research Unit, Oncology Service, Hospital Sao Lucas, Pontifícia Universidade Católica do Rio Grande do Sol, Porto Alegre, Brazil; Division of Medical Oncology and Hematology, Fundación Arturo López Pérez, Santiago, Chile; Chelyabinsk Regional Oncology Center, Chelyabinsk, Russian Federation; Krankenhaus Heitzing, mit Neurologischem Zentrum Rosenhugel, Vienna, Austria; Centro Médico San Roque, Tucumán, Argentina; GlaxoSmithKline, Collegeville, PA; and GlaxoSmithKline, Research Triangle Park, NC., Chen M; From the Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy; Ludwig Oncology Unit, Austin Hospital, Melbourne, Australia; National Oncological Institute, Klenová, Bratislava, Slovakia; Department of Oncology, Military Institute of Medicine, Warsaw, Poland; Department of Urology, Seoul National University College of Medicine, Seoul, Korea; The South West Wales Cancer Institute, Singleton Hospital, Swansea; Cancer Research UK, Department of Medical Oncology, University of Manchester; Christie Hospital National Health Services Foundation Trust, Manchester, United Kingdom; Oncology Research Unit, Oncology Service, Hospital Sao Lucas, Pontifícia Universidade Católica do Rio Grande do Sol, Porto Alegre, Brazil; Division of Medical Oncology and Hematology, Fundación Arturo López Pérez, Santiago, Chile; Chelyabinsk Regional Oncology Center, Chelyabinsk, Russian Federation; Krankenhaus Heitzing, mit Neurologischem Zentrum Rosenhugel, Vienna, Austria; Centro Médico San Roque, Tucumán, Argentina; GlaxoSmithKline, Collegeville, PA; and GlaxoSmithKline, Research Triangle Park, NC., McCann L; From the Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy; Ludwig Oncology Unit, Austin Hospital, Melbourne, Australia; National Oncological Institute, Klenová, Bratislava, Slovakia; Department of Oncology, Military Institute of Medicine, Warsaw, Poland; Department of Urology, Seoul National University College of Medicine, Seoul, Korea; The South West Wales Cancer Institute, Singleton Hospital, Swansea; Cancer Research UK, Department of Medical Oncology, University of Manchester; Christie Hospital National Health Services Foundation Trust, Manchester, United Kingdom; Oncology Research Unit, Oncology Service, Hospital Sao Lucas, Pontifícia Universidade Católica do Rio Grande do Sol, Porto Alegre, Brazil; Division of Medical Oncology and Hematology, Fundación Arturo López Pérez, Santiago, Chile; Chelyabinsk Regional Oncology Center, Chelyabinsk, Russian Federation; Krankenhaus Heitzing, mit Neurologischem Zentrum Rosenhugel, Vienna, Austria; Centro Médico San Roque, Tucumán, Argentina; GlaxoSmithKline, Collegeville, PA; and GlaxoSmithKline, Research Triangle Park, NC., Pandite L; From the Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy; Ludwig Oncology Unit, Austin Hospital, Melbourne, Australia; National Oncological Institute, Klenová, Bratislava, Slovakia; Department of Oncology, Military Institute of Medicine, Warsaw, Poland; Department of Urology, Seoul National University College of Medicine, Seoul, Korea; The South West Wales Cancer Institute, Singleton Hospital, Swansea; Cancer Research UK, Department of Medical Oncology, University of Manchester; Christie Hospital National Health Services Foundation Trust, Manchester, United Kingdom; Oncology Research Unit, Oncology Service, Hospital Sao Lucas, Pontifícia Universidade Católica do Rio Grande do Sol, Porto Alegre, Brazil; Division of Medical Oncology and Hematology, Fundación Arturo López Pérez, Santiago, Chile; Chelyabinsk Regional Oncology Center, Chelyabinsk, Russian Federation; Krankenhaus Heitzing, mit Neurologischem Zentrum Rosenhugel, Vienna, Austria; Centro Médico San Roque, Tucumán, Argentina; GlaxoSmithKline, Collegeville, PA; and GlaxoSmithKline, Research Triangle Park, NC., Roychowdhury DF; From the Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy; Ludwig Oncology Unit, Austin Hospital, Melbourne, Australia; National Oncological Institute, Klenová, Bratislava, Slovakia; Department of Oncology, Military Institute of Medicine, Warsaw, Poland; Department of Urology, Seoul National University College of Medicine, Seoul, Korea; The South West Wales Cancer Institute, Singleton Hospital, Swansea; Cancer Research UK, Department of Medical Oncology, University of Manchester; Christie Hospital National Health Services Foundation Trust, Manchester, United Kingdom; Oncology Research Unit, Oncology Service, Hospital Sao Lucas, Pontifícia Universidade Católica do Rio Grande do Sol, Porto Alegre, Brazil; Division of Medical Oncology and Hematology, Fundación Arturo López Pérez, Santiago, Chile; Chelyabinsk Regional Oncology Center, Chelyabinsk, Russian Federation; Krankenhaus Heitzing, mit Neurologischem Zentrum Rosenhugel, Vienna, Austria; Centro Médico San Roque, Tucumán, Argentina; GlaxoSmithKline, Collegeville, PA; and GlaxoSmithKline, Research Triangle Park, NC., Hawkins RE; From the Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy; Ludwig Oncology Unit, Austin Hospital, Melbourne, Australia; National Oncological Institute, Klenová, Bratislava, Slovakia; Department of Oncology, Military Institute of Medicine, Warsaw, Poland; Department of Urology, Seoul National University College of Medicine, Seoul, Korea; The South West Wales Cancer Institute, Singleton Hospital, Swansea; Cancer Research UK, Department of Medical Oncology, University of Manchester; Christie Hospital National Health Services Foundation Trust, Manchester, United Kingdom; Oncology Research Unit, Oncology Service, Hospital Sao Lucas, Pontifícia Universidade Católica do Rio Grande do Sol, Porto Alegre, Brazil; Division of Medical Oncology and Hematology, Fundación Arturo López Pérez, Santiago, Chile; Chelyabinsk Regional Oncology Center, Chelyabinsk, Russian Federation; Krankenhaus Heitzing, mit Neurologischem Zentrum Rosenhugel, Vienna, Austria; Centro Médico San Roque, Tucumán, Argentina; GlaxoSmithKline, Collegeville, PA; and GlaxoSmithKline, Research Triangle Park, NC.

المصدر: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2023 Apr 10; Vol. 41 (11), pp. 1957-1964.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't; Clinical Trial, Phase III; Multicenter Study; Randomized Controlled Trial

بيانات الدورية: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: PubMed not MEDLINE; MEDLINE

المؤلفون: Zarbá M; FUCA, Instituto Alexander Fleming, CABA C1426ANZ, Argentina.; https://orcid.org/0000-0003-3642-4035., Angel M; Genitourinary Tumors Department, Instituto Alexander Fleming, CABA C1426ANZ, Argentina.; These authors have contributed equally to this work.; https://orcid.org/0000-0002-1463-8887., Losco F; Genitourinary Tumors Department, Instituto Alexander Fleming, CABA C1426ANZ, Argentina.; https://orcid.org/0000-0001-5084-3012., Zarbá JJ; Oncology Department, Hospital Zenon Santillan, San Miguel de Tucuman T4000IAK, Argentina.; https://orcid.org/0000-0003-1013-3993., Pupilli JC; Genitourinary Tumors Department, Sanatorio Británico Rosario, Santa Fé S2000ANZ, Argentina., Chacon MR; Oncology Department, Instituto Alexander Fleming, CABA C1426ANZ, Argentina.; https://orcid.org/0000-0001-6872-4185., Sade JP; Genitourinary Tumors Department, Instituto Alexander Fleming, CABA C1426ANZ, Argentina.; https://orcid.org/0000-0001-9312-5280.

المصدر: Ecancermedicalscience [Ecancermedicalscience] 2022 Dec 02; Vol. 16, pp. 1480. Date of Electronic Publication: 2022 Dec 02 (Print Publication: 2022).

نوع المنشور: Journal Article

بيانات الدورية: Publisher: ecancer Country of Publication: England NLM ID: 101392236 Publication Model: eCollection Cited Medium: Print ISSN: 1754-6605 (Print) Linking ISSN: 17546605 NLM ISO Abbreviation: Ecancermedicalscience Subsets: PubMed not MEDLINE

المؤلفون: Maluf FC; Hospital Israelita Albert Einstein, São Paulo, Brazil.; Beneficência Portuguesa de São Paulo, São Paulo, Brazil.; Latin American Oncology Group (LACOG), Porto Alegre, Brazil., Pereira FMT; Latin American Oncology Group (LACOG), Porto Alegre, Brazil., Silva AG; Latin American Oncology Group (LACOG), Porto Alegre, Brazil.; Oncologia Clínica ICTr, Curitiba, Brazil., Dettino ALA; Latin American Oncology Group (LACOG), Porto Alegre, Brazil.; Hospital AC Camargo, São Paulo, Brazil., Cardoso APG; Hospital Israelita Albert Einstein, São Paulo, Brazil.; Latin American Oncology Group (LACOG), Porto Alegre, Brazil., Sasse AS; Latin American Oncology Group (LACOG), Porto Alegre, Brazil.; Grupo Sonhe, Campinas, Brazil., Soares A; Hospital Israelita Albert Einstein, São Paulo, Brazil.; Latin American Oncology Group (LACOG), Porto Alegre, Brazil.; Centro Paulista de Oncologia, Oncoclínicas, São Paulo, Brazil., Kann AG; Latin American Oncology Group (LACOG), Porto Alegre, Brazil.; Hospital Alemão Oswaldo Cruz, São Paulo, Brazil., Herchenhorn D; Latin American Oncology Group (LACOG), Porto Alegre, Brazil.; Grupo de oncologia D'Or, Rio de Janeiro, Brazil.; Instituto D'Or de ensino e pesquisa, Rio de Janeiro, Brazil., Jardim DLF; Latin American Oncology Group (LACOG), Porto Alegre, Brazil.; Hospital Sírio Libanês, São Paulo, Brazil., Cortés DEL; Clínica Oncólogos del Occidente SAS, Manizales, Colombia., Kater FR; Beneficência Portuguesa de São Paulo, São Paulo, Brazil.; Latin American Oncology Group (LACOG), Porto Alegre, Brazil., Morbeck IAP; Latin American Oncology Group (LACOG), Porto Alegre, Brazil.; Hospital Sírio Libanês, Brasília, Brazil.; Universidade Católica de Brasília, Brasília, Brazil., Reolon JFN; Beneficência Portuguesa de São Paulo, São Paulo, Brazil.; Latin American Oncology Group (LACOG), Porto Alegre, Brazil., Rinck JA Jr; Latin American Oncology Group (LACOG), Porto Alegre, Brazil.; Hospital AC Camargo, São Paulo, Brazil., Zarbá JJ; Hospital Zenon Santillán, Nacional University of Tucumán, Tucumán, Argentina., Sade JP; Latin American Oncology Group (LACOG), Porto Alegre, Brazil.; Instituto Alexander Fleming y de la Universidad Austral, Buenos Aires, Argentina., da Trindade KM; Latin American Oncology Group (LACOG), Porto Alegre, Brazil.; IEP-Instituto de Ensino e Pesquisa Oncocentro, Fortaleza, Brazil., Costa LAGA; Latin American Oncology Group (LACOG), Porto Alegre, Brazil.; Grupo de oncologia D'Or, Rio de Janeiro, Brazil., Dos Santos LV; Beneficência Portuguesa de São Paulo, São Paulo, Brazil., Maia MC; Latin American Oncology Group (LACOG), Porto Alegre, Brazil.; Centro de Oncologia do Paraná, Curitiba, Brazil., Siqueira MB; Latin American Oncology Group (LACOG), Porto Alegre, Brazil.; Grupo de oncologia D'Or, Rio de Janeiro, Brazil., Gillessen S; Oncology Institute of Southern Switzerland (IOSI), Bellinzona and Università della Svizzera Italiana, Lugano, Switzerland.; Manchester Cancer Research Centre, Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom.

المصدر: JCO global oncology [JCO Glob Oncol] 2021 Apr; Vol. 7, pp. 559-571.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 101760170 Publication Model: Print Cited Medium: Internet ISSN: 2687-8941 (Electronic) Linking ISSN: 26878941 NLM ISO Abbreviation: JCO Glob Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Prostatic Neoplasms, Castration-Resistant*/drug therapy, Androgen Antagonists/therapeutic use ; Developing Countries ; Docetaxel/therapeutic use ; Follow-Up Studies ; Humans ; Male

المؤلفون: Scheinberg M; a Rheumatology Section - Orthopedics Department , Hospital Israelita Albert Einstein , São Paulo , Brazil., Pineda C; b Division of Musculoskeletal and Rheumatic Diseases , Instituto Nacional de Rehabilitación Luis Guillermo Ibarra Ibarra , Mexico City , Mexico., Castañeda-Hernández G; c Department of Pharmacology , Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional , Mexico City , Mexico., Zarbá JJ; d Oncology Department , Hospital Centro de Salud Zenón J. Santillán , San Miguel de Tucumán , Argentina.; e Facultad de Medicina, Universidad Nacional de Tucumán , San Miguel de Tucumán , Argentina., Damião A; f Department of Gastroenterology , University of São Paulo Medical School , São Paulo , Brazil., Arantes LH Jr; g Pfizer Inc , New York , NY , USA., Jacobs I; g Pfizer Inc , New York , NY , USA.

المصدر: MAbs [MAbs] 2018 Aug/Sep; Vol. 10 (6), pp. 827-842. Date of Electronic Publication: 2018 Aug 29.

نوع المنشور: Journal Article; Review

بيانات الدورية: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101479829 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1942-0870 (Electronic) Linking ISSN: 19420862 NLM ISO Abbreviation: MAbs Subsets: MEDLINE

مواضيع طبية MeSH: Antibodies, Monoclonal/*therapeutic use , Biological Products/*therapeutic use , Biosimilar Pharmaceuticals/*therapeutic use , Inflammation/*drug therapy , Neoplasms/*drug therapy, Drug Approval/methods ; Drug Therapy/methods ; Drug Therapy/trends ; Forecasting ; Humans ; Inflammation/immunology ; Latin America ; Neoplasms/immunology